Research ExplorerPublicationsPopulation-based and controlled study to evaluate neuroblast...

Population-based and controlled study to evaluate neuroblastoma screening at one year of age in Germany: interim results.

Standard

Population-based and controlled study to evaluate neuroblastoma screening at one year of age in Germany: interim results. / Schilling, F H; Berthold, F; Erttmann, Rudolf; Michaelis, J; Spix, C; Sander, J; Schwarz, K; Treuner, J.

In: Med Pediatr Oncol, Vol. 35, No. 6, 6, 2000, p. 701-704.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Schilling, FH, Berthold, F, Erttmann, R, Michaelis, J, Spix, C, Sander, J, Schwarz, K & Treuner, J 2000, 'Population-based and controlled study to evaluate neuroblastoma screening at one year of age in Germany: interim results.', Med Pediatr Oncol, vol. 35, no. 6, 6, pp. 701-704. <http://www.ncbi.nlm.nih.gov/pubmed/11107150?dopt=Citation>

APA

Schilling, F. H., Berthold, F., Erttmann, R., Michaelis, J., Spix, C., Sander, J., Schwarz, K., & Treuner, J. (2000). Population-based and controlled study to evaluate neuroblastoma screening at one year of age in Germany: interim results. Med Pediatr Oncol, 35(6), 701-704. [6]. http://www.ncbi.nlm.nih.gov/pubmed/11107150?dopt=Citation

Vancouver

Schilling FH, Berthold F, Erttmann R, Michaelis J, Spix C, Sander J et al. Population-based and controlled study to evaluate neuroblastoma screening at one year of age in Germany: interim results. Med Pediatr Oncol. 2000;35(6):701-704. 6.

Bibtex

@article{18e5718097df488a801d486bc2a592f5,
title = "Population-based and controlled study to evaluate neuroblastoma screening at one year of age in Germany: interim results.",
abstract = "BACKGROUND: The German Neuroblastoma Screening Project is the first controlled and population-based screening study to evaluate the presumed benefit of neuroblastoma mass screening at 1 year of age (10-18 months). PROCEDURE: Screening takes place in 6 of the 16 German states; children from the remainder serve as controls. The German Childhood Cancer Registry enables a mostly complete follow-up and detection of false-negative patients. RESULTS: Up to December, 1999, 1,199,165 children were examined for urinary catecholamine metabolites and 124 cases of neuroblastoma were detected preclinically, giving a detection rate of 10.3/100,000. Within this cohort, 33 false-negative cases were found. CONCLUSIONS: The results of this screening program will be crucial for further implementation of neuroblastoma screening.",
author = "Schilling, {F H} and F Berthold and Rudolf Erttmann and J Michaelis and C Spix and J Sander and K Schwarz and J Treuner",
year = "2000",
language = "Deutsch",
volume = "35",
pages = "701--704",
number = "6",

}

RIS

TY - JOUR

T1 - Population-based and controlled study to evaluate neuroblastoma screening at one year of age in Germany: interim results.

AU - Schilling, F H

AU - Berthold, F

AU - Erttmann, Rudolf

AU - Michaelis, J

AU - Spix, C

AU - Sander, J

AU - Schwarz, K

AU - Treuner, J

PY - 2000

Y1 - 2000

N2 - BACKGROUND: The German Neuroblastoma Screening Project is the first controlled and population-based screening study to evaluate the presumed benefit of neuroblastoma mass screening at 1 year of age (10-18 months). PROCEDURE: Screening takes place in 6 of the 16 German states; children from the remainder serve as controls. The German Childhood Cancer Registry enables a mostly complete follow-up and detection of false-negative patients. RESULTS: Up to December, 1999, 1,199,165 children were examined for urinary catecholamine metabolites and 124 cases of neuroblastoma were detected preclinically, giving a detection rate of 10.3/100,000. Within this cohort, 33 false-negative cases were found. CONCLUSIONS: The results of this screening program will be crucial for further implementation of neuroblastoma screening.

AB - BACKGROUND: The German Neuroblastoma Screening Project is the first controlled and population-based screening study to evaluate the presumed benefit of neuroblastoma mass screening at 1 year of age (10-18 months). PROCEDURE: Screening takes place in 6 of the 16 German states; children from the remainder serve as controls. The German Childhood Cancer Registry enables a mostly complete follow-up and detection of false-negative patients. RESULTS: Up to December, 1999, 1,199,165 children were examined for urinary catecholamine metabolites and 124 cases of neuroblastoma were detected preclinically, giving a detection rate of 10.3/100,000. Within this cohort, 33 false-negative cases were found. CONCLUSIONS: The results of this screening program will be crucial for further implementation of neuroblastoma screening.

M3 - SCORING: Zeitschriftenaufsatz

VL - 35

SP - 701

EP - 704

IS - 6

M1 - 6

ER -